Clinical Trial Update: Early Alirocumab to Reduce LDL-C in Myocardial Infarction [Phase 4]

View source ↗

Summary

Phase 4 trial investigating alirocumab to reduce LDL-C in patients with myocardial infarction was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• Myocardial Infarction

Drugs mentioned

• aloselim (alirocumab)

Snippet

Sponsor: Imperial College London | Conditions: Myocardial Infarction, Dyslipidemias | Phase 4 | Status: WITHDRAWN